U.S. markets closed

Johnson & Johnson (JNJ)

NYSE - Nasdaq Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
145.74+0.97 (+0.67%)
Al cierre: 04:00PM EDT
145.66 -0.08 (-0.05%)
Fuera de horario: 05:43PM EDT

Johnson & Johnson

One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States
732 524 0400
https://www.jnj.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - General
Empleados a tiempo completo131,900

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Joaquin DuatoCEO & Chairman6.21M14.99M1963
Dr. Peter M. Fasolo Ph.D.Executive VP & Chief Human Resources Officer2.15MN/D1963
Ms. Jennifer L. TaubertExecutive VP & Worldwide Chairman of Innovative Medicine3.1MN/D1964
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine, R&D8.57MN/D1958
Mr. Robert J. Decker Jr.Controller & Chief Accounting OfficerN/DN/D1972
Mr. James SwansonExecutive VP & Chief Information OfficerN/DN/D1966
Ms. Jessica MooreVice President of Investor RelationsN/DN/DN/D
Mr. Dirk BrinckmanChief Compliance OfficerN/DN/DN/D
Ms. Elizabeth ForminardExecutive VP & General CounselN/DN/D1971
Dr. Guy J. Lebeau M.D.Group Chairman of MD&D Business - EMEAN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Gestión corporativa

La calificación ISS Governance QuickScore de Johnson & Johnson a partir del 1 de abril de 2024 es 2. Las puntuaciones principales son Auditoría: 6; Junta: 4; Derechos del accionista: 2; Compensación: 3.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.